Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9178197 | 0.96 | HRH4 (0.38) | ADORA1ADORA3ADORA2AHRH4SMPD3 | |
| SCHEMBL22858756 | 0.80 | HRH4 (0.36) | HRH4SMPD3GAAHTTHPGD | |
| SCHEMBL8957952 | 0.77 | ALDH1A1 (0.41) | HRH4 | |
| SCHEMBL12989184 | 0.77 | HRH4 (0.38) | ADORA1ADORA3ADORA2AHRH4DDAH1 | |
| SCHEMBL13318361 | 0.75 | HRH4 (0.35) | HRH4SMPD3 | |
| SCHEMBL23642016 | 0.75 | PDCD1 (0.40) | ADORA1ADORA3ADORA2ADDAH1 | |
| Hydrochloric Acid SCHEMBL14716148 | 0.73 | HDAC6 (0.36) | HRH4SMPD3HTT | |
| Hydrochloric Acid SCHEMBL28836282 | 0.73 | HRH4 (0.34) | HRH4SMPD3 | |
| SCHEMBL21663010 | 0.73 | L3MBTL1 (0.47) | ADORA1ADORA3ADORA2ADDAH1TNKS2 | |
| SCHEMBL18711813 | 0.73 | HPGD (0.54) | KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | ADORA1 1800/4885ADORA3 1264/4885ADORA2A 1457/4885 |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | ADORA1 4626/4885ADORA3 4761/4885ADORA2A 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.